ARHGAP39

Across TCGA pan-cancer cohorts, ARHGAP39 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGAP39 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ARHGAP39 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGAP39 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SCLC, COAD, and UCEC are the cancer types where ARHGAP39 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	III,IV	0.082	0.548	.003	24	view →
COAD	OS	Median	All	0.500	0.871	.025	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →
SKCM	DFS	Median	II,III,IV	0.894	0.675	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGAP39–SCLC (DFS)

Open the SCLC breakdown →